Moderna secures $176M BARDA grant for mRNA flu vaccine development

Moderna has secured a significant financial boost with a $176 million project award from BARDA's Rapid Response Partnership Vehicle (RRPV) consortium. This funding is aimed at accelerating the development of mRNA-based vaccines for pandemic influenza.

The primary focus of this initiative is to complete the final development stages of an mRNA vaccine targeting the pre-pandemic H5 influenza virus. This particular subtype is known for causing severe avian influenza and carries a substantial risk of transmission to humans. The financial support from BARDA is also intended to enhance preparedness for future public health emergencies.

In 2023, Moderna commenced a phase 1/2 clinical trial to assess the safety and immune response of its investigational mRNA-1018 pandemic influenza vaccine. This study involves adult participants aged 18 and older and includes vaccine candidates for both H5 and H7 avian influenza viruses. Results from this trial are anticipated later this year.

The RRPV, funded by BARDA, is a consortium that unites various members specializing in medical technology, vaccines, and therapeutics. Its mission is to facilitate faster partnerships, enhance responsiveness, and meet the growing demand for developing future medical countermeasure products.